Iacono A
Cattedra di Cardiologia, Istituto Medico-Chirurgico di Cardiologia, Seconda Università degli Studi, Napoli.
Cardiologia. 1997 Dec;42(12):1251-5.
In order to assess the efficacy of 3-month subcutaneous treatment with calcium heparin 12,500 IU twice daily in preventing left ventricular thrombosis and its complications a prospective, controlled, randomized trial was carried out in 204 patients with acute anterior myocardial infarction consecutively enrolled in seven Italian hospitals. Left ventricular thrombosis was diagnosed by means of two-dimensional echocardiography performed at baseline, after 10 and 90 days of treatment. The incidence of thrombosis at the baseline echocardiogram was not significantly different between the treatment and control groups, whereas a significantly lower incidence of thrombi was observed in treated than in control group both on day 10 (3/86, 3.5% and 13/85, 15.3%, respectively; p < 0.05) and day 90 (1/65, 1.5% and 6/57, 10.5%, respectively; p < 0.05). The total incidence of thrombi after 3 months of therapy was significantly lower in calcium heparin-treated patients (19/106, 17.9%) than in controls (31/98, 31.6%; p < 0.05). The incidence of cardiac events (death, reinfarction, angina) in the two groups during the 3-month treatment period was not significantly different. Two embolic events, one cerebral and one pulmonary, occurred in the control group, both after day 10 of treatment.
为评估每日两次皮下注射12,500国际单位钙肝素进行3个月治疗预防左心室血栓形成及其并发症的疗效，在意大利七家医院连续招募的204例急性前壁心肌梗死患者中开展了一项前瞻性、对照、随机试验。通过在基线、治疗10天和90天后进行二维超声心动图诊断左心室血栓形成。治疗组和对照组在基线超声心动图时的血栓形成发生率无显著差异，而在治疗第10天（分别为3/86，3.5%和13/85，15.3%；p<0.05）和第90天（分别为1/65，1.5%和6/57，10.5%；p<0.05）时，治疗组的血栓发生率均显著低于对照组。治疗3个月后，钙肝素治疗患者的血栓总发生率（19/106，17.9%）显著低于对照组（31/98，31.6%；p<0.05）。两组在3个月治疗期内心脏事件（死亡、再梗死、心绞痛）的发生率无显著差异。对照组发生了两例栓塞事件，一例为脑栓塞，一例为肺栓塞，均发生在治疗第10天后。
